| 指数 | 开盘价 | 收盘价 | 近一交易日% | 近20交易日% | | --- | --- | --- | --- | --- | | 上证综指 | 4,128 | 4,128 | 0.13 | -0.25 | | 深证成指 | 14,201 14,211 | | 0.02 | 0.29 | | 创业板指 | 3,322 | 3,321 | -0.37 | -0.04 | | 恒生指数 | 27,203 27,183 | | 0.58 | 1.25 | | 日经225 56,812 57,651 | | | 2.28 | 7.66 | | 富时100 10,386 10,354 | | | -0.31 | 2.14 | | 道琼斯工业 | 50,193 50,188 | | 0.10 | 1.21 | | 标普500 | 6,974 | 6,942 | -0.33 | -0.51 | | 纳斯达克 | 23,271 23,102 | | -0.59 | -2.66 | | 主要市场股指表现 | | | | | | 10.00 | 近一交易日% | | 近20交易日% | | | （%） 8.00 | ...

美股道指续创新高，人工智能忧虑波及券商股。港股三大指数继续高开，恒指涨0.23%，国指涨 0.17%，恒生科技指数涨0.21%。权重科技股多数继续反弹，AI应用概念股继续上涨，龙头股智谱高开 近5%有望再创历史新高，阜博集团、商汤等纷纷上涨，生物医药股亦集体活跃，再鼎医药、药明生物 涨超3%。另外，半导体股、餐饮股、石油股部分走低，权重股中芯国际跌超2%。(格隆汇) ...

当地时间2月10日（周二），美国股市三大股指收盘涨跌不一, 其中道琼斯工业指数收涨，收盘和盘中均再创历 史新高。 美股存储芯片概念股成为市场焦点之一，当天多只存储芯片概念股大跌，闪迪跌超7%。 当地时间2月10日（周二），美国股市三大股指收盘涨跌不一，其中道琼斯工业指数涨0.1%，报50188.14点，收 盘和盘中均创历史新高；标准普尔500指数跌0.33%，报6941.81点，该指数尾盘出现一波跳水；纳斯达克指数跌 0.59%，报23102.47点。 | 分时 多日 1分 5分 15分 30分 60分 日 周 月 更多 F9 不复权 超级量加 面线 工具 谷 》 | | | | | | 道琼斯工业平均 | | | --- | --- | --- | --- | --- | --- | --- | --- | | DJI.GI(删除断工业平均) 2025/10/03 收 46758.28 幅 0.51%(238.56) 开 46583.95 商 47049.64 低 46566.87 换 0.00% 振 | ಸಿಲ | | 50188.14 +52.27 +0.10% | | | | DJI | | MAS ...

大家早上壕！ 先看海外要闻： 重磅就业报告公布前AI担忧重燃，标普纳指回落，但道指三日连创新高；收盘标普500跌0.33%，道指涨0.10%，纳指跌0.59%。 新AI工具引发行业前景忧虑，财富管理类股暴跌，嘉信理财收跌超7%；"科技七巨头"中，特斯拉涨近2%独涨、谷歌跌近2%领跌；存储芯片股大 幅回落，闪迪跌超7%。 纳斯达克金龙中国指数收涨0.87%，九紫新能收涨将近90%，禾赛、再鼎医药涨超6%。 美国零售数据逊色，美债价格加速上涨、收益率降幅扩大，十年期美债收益率创近一个月新低，美元指数盘中跌幅扩大、再创逾一周新低。 今日券商策略前瞻： 方正证券指出，技术面来看，沪指收出一根缩量小阳线，指数在4110点（20日均线）附近获得支撑，但上方4130-4140点区域构成短期压力。目 前指数处于上有压力、下有支撑的箱体震荡区间。成交额近期显示交投活跃度一般，资金观望情绪浓厚。节前资金观望情绪浓厚，春季行情继续 向节后演绎，没有只涨不退的潮水，4100点反复夯实为后续行情打下基础。 今日题材方面： 离岸人民币又创将近三年新高，近三年来首次盘中涨破6.91；比特币盘中跌破6.8万美元、较日高跌近4%。 金银铜和原 ...

当地时间2月10日，美股市场呈现出显著的分化格局。在道琼斯工业平均指数盘中刷新历史新高的同 时，纳斯达克指数与标普500指数却由涨转跌，回吐早盘涨幅。与此同时，国际大宗商品市场维持弱势 震荡，地缘政治风险因特朗普的最新表态而再度升温。 在国际贵金属市场，金价与银价延续弱势震荡态势。截至北京时间2月11日5:50，COMEX黄金期货与伦 敦金现货价格分别报5048.8美元/盎司和5022.85美元/盎司，微跌0.6%和0.71%；白银价格波动更甚， COMEX白银期货跌超2%，伦敦银现货跌超3%，分别徘徊在80.475美元/盎司和80.711美元/盎司附近。 中信期货研判认为，在金价维持高位运行的背景下，白银仍具备相对收益空间，但需警惕高波动环境下 的阶段性回撤风险。 原油方面，NYMEX原油期货与ICE布油期货主力合约微跌，分别报64.19美元/桶和69.01美元/桶。信达 期货分析指出，原油市场逻辑已从事件驱动溢价切换至基本面交易，中期来看，"供应过剩"压力是更可 持续的定价锚，空头主导格局明确，油价趋势性承压概率较大。 消息面上，地缘政治不确定性为市场增添变数。据央视新闻报道，美国总统特朗普当地时间2月1 ...

Market Performance - The Dow Jones Industrial Average reached a new all-time high, peaking at 50,512.79 points during the day, closing with a slight gain of 0.1% [2] - The Nasdaq and S&P 500 indices turned negative, with declines of 0.59% and 0.33% respectively [2] - Large-cap tech stocks showed mixed results, with Tesla rising nearly 2%, while major players like Microsoft, Apple, Nvidia, Amazon, and Meta experienced declines [4][5] Chinese Stocks - The Nasdaq Golden Dragon China Index saw a continuous rise for four trading days, increasing by nearly 1% [5] - Notable Chinese stocks such as Shengda Technology and Dingdong Maicai surged over 7%, while Hesai Technology and Zai Ding Pharmaceutical rose over 6% [5][6] Precious Metals - International gold prices fluctuated around $5,000 per ounce, while silver prices hovered near $80 per ounce [8] - As of February 11, gold futures and spot prices fell by 0.6% and 0.71%, respectively, while silver futures and spot prices dropped over 2% and 3% [8] - Analysts suggest that while gold remains at high levels, silver still has relative upside potential, although caution is advised due to high volatility [10] Oil Market - International oil prices experienced slight declines, with NYMEX crude futures and ICE Brent futures reported at $64.19 per barrel and $69.01 per barrel, respectively [8]

Market Performance - The Dow Jones Industrial Average reached a new all-time high, peaking at 50,512.79 points, closing up by 0.1% [3][16] - The Nasdaq and S&P 500 indices turned negative, with declines of 0.59% and 0.33% respectively [3][16] - Large-cap tech stocks showed mixed results, with Tesla rising nearly 2%, while Microsoft, Apple, Nvidia, Amazon, and Meta all declined [6][17] Chinese Stocks - The Nasdaq Golden Dragon China Index saw a continuous rise for four trading days, increasing by nearly 1% [2][19] - Notable gains were observed in companies such as Shengda Technology and Dingdong Maicai, both rising over 7% [19] Commodity Prices - International gold prices fluctuated around $5,000 per ounce, while silver prices hovered near $80 per ounce [4][20] - As of February 11, gold futures and spot prices fell by 0.6% and 0.71% respectively, while silver futures dropped over 2% [20][21] Oil Market - International oil prices experienced slight declines, with NYMEX crude oil futures at $64.19 per barrel and ICE Brent crude at $69.01 per barrel [20][21] - The oil market is transitioning from event-driven pricing to fundamental trading, with a higher likelihood of a trend towards oversupply pressure [22]

2月10日早盘，港股市场创新药再度活跃，再鼎医药、信达生物、科伦博泰生物、药明生物、映恩 生物等领涨，恒生医药ETF（159892）盘中涨超2%。 消息面来看，信达生物近日宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全 球研发，首付款达3.5亿美元，里程碑付款有望达85亿美元。 东海证券表示，创新药板块靓丽的业绩表现，充分验证了国产创新药商业模式的有效性，医保加持 下的核心产品放量成为业绩增长基础，BD等对外合作则成为业绩增厚的重要抓手。 每日经济新闻 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com （责任编辑：张晓波 ） ...

Core Viewpoint - The innovative drug concept stocks have generally risen in the morning session, indicating positive market sentiment towards this sector [1][2]. Group 1: Stock Performance - CSPC Pharmaceutical Group (01093) increased by 7.16%, trading at HKD 10.48 [1][2]. - WuXi Biologics (02269) rose by 5.54%, with a price of HKD 40.36 [1][2]. - CanSino Biologics-B (02162) saw a gain of 5.45%, priced at HKD 60.95 [1][2]. - Innovent Biologics (01801) experienced a 5.15% increase, trading at HKD 89.8 [1][2]. - Zai Lab (09688) climbed by 4.9%, with shares priced at HKD 14.76 [1][2].

Core Viewpoint - The innovative pharmaceutical sector is experiencing a significant rise, with multiple companies reporting substantial stock increases due to recent high-profile collaborations and a positive outlook for revenue growth in the industry [1] Group 1: Stock Performance - Innovative drug concept stocks are generally rising, with notable increases: - CSPC Pharmaceutical Group (01093) up 7.16% to HKD 10.48 - WuXi Biologics (02269) up 5.54% to HKD 40.36 - CanSino Biologics-B (02162) up 5.45% to HKD 60.95 - Innovent Biologics (01801) up 5.15% to HKD 89.8 - Zai Lab (09688) up 4.9% to HKD 14.76 [1] Group 2: Collaborations and Partnerships - Significant collaborations have been announced in 2026, including: - CSPC Pharmaceutical Group's partnership with AstraZeneca worth up to USD 18.5 billion - Rongchang Biologics' agreement with AbbVie valued at USD 5.6 billion - Various innovative drug export formats are emerging, such as "single product licensing" and "technology platform + heavyweight single product" [1] Group 3: Industry Outlook - According to Kaiyuan Securities, the revenue growth in innovative drugs is accelerating, with over 70% of companies expected to achieve positive revenue growth by 2025 - The innovative drug sector has seen a correction over the past two quarters, but long-term prospects indicate that many quality stocks offer attractive valuation opportunities - It is recommended to increase allocation in this sector, focusing on companies with established overseas operations and high clinical data performance [1]